Moderna
MRNA
#298
Rank
NZ$142.54 B
Marketcap
NZ$352.29
Share price
-3.16%
Change (1 day)
717.99%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

P/S ratio for Moderna (MRNA)

P/S ratio as of November 2026 (TTM): 35.9

According to Moderna 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.7. At the end of 2026 the company had a P/S ratio of 12.1.

P/S ratio history for Moderna from 2018 to 2026

PS ratio at the end of each year

Year P/S ratio Change
202612.192.51%
20256.2729.96%
20244.83-14.02%
20235.6153.56%
20223.66-37.03%
20215.81-96.15%
20201519.95%
2019137235.08%
201840.9

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
6.59-81.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
5.00-86.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Merck
MRK
4.93-86.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
10.4-71.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
3.95-88.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Arrowhead Pharmaceuticals
ARWR
8.95-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA